ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy

Not Applicable

Recruiting

• Conditions: Lung Cancer; Head and Neck Cancer; Gastrointestinal Cancer
• Interventions: Device: ChatBot

• Registration Number: NCT05318027
• Lead Sponsor: Abramson Cancer Center at Penn Medicine

Brief Summary

Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rates of excess triage visits

Correlate changes in activity and early symptom management to emergency department visits, unplanned inpatient hospitalizations and treatment breaks

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-12-06
• Study First Submitted QC: 2022-04-07
• Study First Posted: 2022-04-08
• Study Start: 2023-05-22
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-06
• Last Update Posted: 2025-03-07
• Primary Completion: 2025-12
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• Adults (age >18 years) with a diagnosis of a head and neck, lung, gastrointestinal cancer, that are receiving concurrent chemotherapy and radiation treatment.
• Possession of a mobile device that can receive SMS texts and can deliver FitBit data wirelessly
• Ability read and respond in English
• Ability to provide informed consent to participate in the study

Exclusion Criteria

• Patients who are bed bound at baseline (ECOG 4)
• Patients who rely on a wheelchair for ambulation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Activity Monitoring and ChatBot	ChatBot	Patients will receive standard of care chemotherapy and radiation therapy regimens, activity monitoring and utilize a ChatBot

Primary Outcome Measures

Name	Time	Method
Number of triage visits	13 weeks	Difference between Poisson event rates of triage visits between intervention and control arms

Secondary Outcome Measures

Name	Time	Method
Count of unplanned inpatient hospitalization	13 weeks
Count of treatment breaks	13 weeks
Count of emergency department visits	13 weeks
Quality of Life scores	13 weeks

Trial Locations

Locations (1)

Abramson Cancer Center of the University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States